Evaluation of T- and NK-cell-targeted therapies: is there a role for rituximab prophylaxis?
Splizimomab, an antibody that targets CD2, was studied in the treatment of T and natural killer cell lymphoma and was found to be associated with Epstein-Barr virus lymphoproliferative disease. B cell depletion may provide a platform for further evaluation of this and other promising antibody approaches that result in T cell depletion.
Ambinder
Richard F
RF
Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. ambinri@jhmi.edu
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology / Q000821:virology; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D008212:Lymphocyte Depletion; D008232:Lymphoproliferative Disorders / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control*; D000069283:Rituximab; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab